Literature DB >> 4027505

Allopurinol treatment of renal calcium stone disease.

B Fellström, U Backman, B G Danielson, K Holmgren, G Johansson, M Lindsjö, S Ljunghall, B Wikström.   

Abstract

Thirty-one calcium stone patients were treated with 300 mg allopurinol daily during a mean follow-up period of 2 years. They were also given advice on diet and fluid intake. The effects on the recurrence rate of stones were compared with the effects on the recurrence rate in 43 calcium stone patients who were given similar advice on diet and fluid intake but were not treated with allopurinol. In both groups there was a reduction in the recurrence rate but no difference between patients treated with allopurinol and the control group. Some patients with only hyperuricosuria prior to treatment seemed to benefit from allopurinol treatment, whereas those with hypercalciuria continued to form stones with the same frequency. Allopurinol treatment in calcium stone disease appears less effective than treatment with thiazides, magnesium hydroxide or orthophosphate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027505     DOI: 10.1111/j.1464-410x.1985.tb06291.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

Review 1.  Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.

Authors:  David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

2.  Relationship of plasma and urine composition to recurrence of calcium urinary stones in patients on drug therapy.

Authors:  K Kohri; T Umekawa; Y Ishikawa; Y Katayama; M Kodama; M Takada; Y Katoh; K Kataoka; M Iguchi; T Kurita
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

3.  Characterisation of risk factors for stones in hyperuricosuric men attending a stone clinic.

Authors:  Valerie Walker; Paul Cook; Damian G Griffin
Journal:  Urolithiasis       Date:  2014-06-04       Impact factor: 3.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.